We are live on
!
Find out more
ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
79 hedge funds and large institutions have $115M invested in Adaptimmune Therapeutics in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 26 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less capital invested
Capital invested by funds: $ → $
0.25% less ownership
Funds ownership: 10.93% → 10.68% (-0.25%)
42% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 26
Holders
79
Holding in Top 10
2
Calls
–
Puts
–
Top Buyers
| 1 | +$1.05M | |
| 2 | +$633K | |
| 3 | +$287K | |
| 4 |
Renaissance Technologies
New York
|
+$193K |
| 5 |
Millennium Management
New York
|
+$79.5K |
Top Sellers
| 1 | -$884K | |
| 2 | -$696K | |
| 3 | -$612K | |
| 4 |
Citigroup
New York
|
-$454K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$440K |